Hence, the preoperative, noninvasive MRI prediction of CDKN2A/B is of great value, as there are currently no clinically validated imaging-based markers for predicting CDKN2A/B homozygous deletion in gliomas. This evidence concerns the gene CDKN2A and glioma.